Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 5/20 | 0.44 |
| ▸ | SYK | P43405 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1616605 | 0.90 | MAPK1 (0.53) | MAPK1GABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL1616894 | 0.89 | MAPK1 (0.45) | MAPK1MEN1KMT2APKMGAA | |
| SCHEMBL5767699 | 0.86 | MAPK1 (0.55) | MAPK1MEN1KMT2APKMGAA | |
| SCHEMBL27994454 | 0.86 | CA12 (0.54) | MAPK1MEN1KMT2APKMGAA | |
| SCHEMBL10341241 | 0.85 | MEN1 (0.46) | MAPK1GABRA1MEN1KMT2APKM | |
| SCHEMBL1178859 | 0.84 | MEN1 (0.55) | MAPK1MEN1KMT2AGAAMAPT | |
| SCHEMBL621551 | 0.84 | MAPT (0.53) | MAPK1MEN1KMT2APKMGAA | |
| SCHEMBL2723624 | 0.84 | MAPK1 (0.57) | MAPK1GABRA1GABRA3MEN1KMT2A | |
| SCHEMBL1040706 | 0.83 | MAPT (0.54) | MAPK1MEN1KMT2AGAANPSR1 | |
| SCHEMBL6202051 | 0.82 | MAPT (0.48) | MAPK1MEN1KMT2APKMGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923457-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923457-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20110053934-A1 | COMPOUNDS AND METHODS OF TREATMENT | GLAXOSMITHKLINE LLC (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053934-A1 | COMPOUNDS AND METHODS OF TREATMENT | GLAXOSMITHKLINE LLC (US) | 2011-03-03 | — | — | US | disclosed |
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | AGOURON PHARMACEUTICALS, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | AGOURON PHARMACEUTICALS, INC. | 2009-03-12 | — | — | US | disclosed |
| US-20080234267-A1 | Compounds and Methods of Treatment | SMITHKLINE BEECHAM CORPORATION | 2008-09-25 | — | — | US | disclosed |
| US-7381824-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381824-B2 | Quinoline derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2008-06-03 | — | — | US | disclosed |
| EP-1042295-B1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-0793656-B1 | NOVEL BENZYL PYRIMIDINES | BASILEA PHARMACEUTICA AG (CH) | 2003-03-26 | — | — | EP | disclosed |
| EP-1042295-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2000-10-11 | — | — | EP | disclosed |
| US-6093732-A | PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| WO-1999032450-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5763450-A | BACTERICIDES; TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0793656-A1 | NOVEL BENZYL PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016046-A2 | NOVEL BENZYL PYRIMIDINES | F. HOFFMANN-LA ROCHE AG (CH) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069316-A1 | NOVEL QUINOLINE DERIVATIVES | COQ8B, COQ8A, MCM5 | MAPK1 1672/4885GABRA1 4738/4885GABRG2 4778/4885 |
| US-20110053934-A1 | COMPOUNDS AND METHODS OF TREATMENT | RET, ABL1, PRKACA | MAPK1 587/4885GABRA1 2417/4885GABRG2 2038/4885 |
| US-20080234267-A1 | Compounds and Methods of Treatment | RET, ABL1, PRKACA | MAPK1 587/4885GABRA1 2417/4885GABRG2 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.